Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi

Söylemez, Elif; Atakli, Hayrunisa Dilek; Öztürk, Oya; Aksoy, Duygu; Alpaydın Baslo, Sezin

doi:10.14744/epilepsi.2019.83788

Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi

Oya ÖZTÜRK, (Bakırköy Profesör Doktor Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, İstanbul, Türkiye)

Sezin ALPAYDIN BASLO, (Bakırköy Profesör Doktor Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, İstanbul, Türkiye)

Dilek ATAKLI, (Bakırköy Profesör Doktor Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, İstanbul, Türkiye)

Elif SÖYLEMEZ, (Bağcılar Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, İstanbul, Türkiye)

Duygu AKSOY (Doktor Burhan Nalbantoğlu Devlet Hastanesi, Nöroloji Kliniği, Lefkoşa, Kuzey Kıbrıs Türk Cumhuriyeti)

Epilepsi

861 0

Yıl: 2020 Cilt: 26 Sayı: 2 Sayfa Aralığı: 115 - 122 Metin Dili: Türkçe DOI: 10.14744/epilepsi.2019.83788 İndeks Tarihi: 08-12-2020

Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi

Öz:

Amaç: Uzun süreli antiepileptik ilaç kullanımı kemik mineral dansitesinde azalma, osteoporoz ve kırık riski ile ilişkisi bulunmuştur. Kemik mineral metabolizması üzerindeki etkileri tam olarak bilinmemekle beraber ana mekanizma, antiepileptiklerin neden olduğu D vitamini eksikliğineodaklanmış görünmektedir. Bu çalışmanın temel amacı karbamazepin, valproik asit, okskarbazepin, levetirasetam ve lamotrijin monoterapilerinin epilepsi hastalarının kemik sağlığı durumuna etkilerini araştırmaktır.Gereç ve Yöntem: Bu çalışmaya en az bir yıl boyunca monoterapi olarak karbamazepin (n=75), valproik asit (n=75), okskarbazepin (n=37), levetirasetam (n=54) veya lamotrijin (n=29) kullanan 270 epilepsi hastası ve 71 sağlıklı kontrol dahil edildi. Cinsiyet, yaş, günlük ilaç dozu, serumilaç seviyesi ve hastalık süresi gibi hastaların demografik ve klinik özellikleri kaydedildi. Ek olarak, katılımcıların D vitamini, kalsiyum, iyonizekalsiyum ve total protein düzeyleri ileriye yönelik olarak değerlendirildi.Bulgular: Kontrol grubunda D vitamini eksikliği %47.9 oranında saptanırken, epilepsi hastalarının tümüne bakıldığında %78.5 oranında bulundu. Karbamazepin, valproik asit, okskarbazepin ve levetirasetam gruplarının D vitamini düzeyleri kontrol grubuna kıyasla anlamlı olarakdüşük ve D vitamini eksiklik sıklıkları da kontrol grubuna göre anlamlı derecede yüksek bulundu. Valproik asit ve levetirasetam gruplarında ilaçkullanım süresi ile D vitamini düzeyi arasında negatif bir korelayon saptandı.Sonuç: D vitamini eksikliği uzun süreli antiepileptik ilaç kullanan epilepsi hastalarında sıktır ve bu popülasyonda kırık riskinin artmasına kısmenkatkıda bulunabilir. Çalışmamızın sonuçları, epilepsi hastalarının D vitamini seviyelerinin düzenli olarak değerlendirilmesi gerektiğini göstermektedir.

Anahtar Kelime:

Association of Vitamin D Deficiency with Antiepileptic Drugs in Patients with Epilepsy

Öz:

Objectives: Long-term usage of antiepileptic drugs is associated with abnormal bone mineral metabolism, osteoporosis and an increased risk of fracture. The main mechanism seems to be focused on vitamin D deficiency that arises from antiepileptics. The primary objective of the present study was to investigate the effects of carbamazepine, valproic acid, oxcarbazepine, levetiracetam and lamotrigine monotherapies on the bone health status of the patients with epilepsy. Methods: This study included 270 patients with epilepsy who underwent carbamazepine (n=75), valproic acid (n=75), oxcarbazepine (n=37), levetiracetam (n=54) or lamotrigine (n=29) monotherapy for at least one year and 71 healthy controls. The demographic and clinical features of the patients were noted. The vitamin D, calcium, ionized calcium and total protein levels of the participants were prospectively evaluated. Results: Vitamin D deficiency was found as 47.9% in the control group and 78.5% in the patients with epilepsy. The vitamin D levels of the patients taking carbamazepine, valproic acid, oxcarbazepine and levetiracetam were significantly lower than those of the control group. In addition, vitamin D deficiency frequencies in these groups were significantly higher than the control group. A negative correlation was found between the duration of the drug use and vitamin D levels in the valproic acid and levetiracetam groups. Conclusion: Vitamin D deficiency is common in patients with epilepsy who have long-term use of antiepileptic drugs and may contribute in part to the increased risk of fractures in this population. The findings obtained in this study suggest that the vitamin-D levels of patients with epilepsy should be regularly assessed.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Dussault PM, Lazzari AA. Epilepsy and osteoporosis risk. Curr Opin Endocrinol Diabetes Obes 2017;24(6):395–401.
2. Shiek Ahmad B, Hill KD, O’Brien TJ, Gorelik A, Habib N, Wark JD. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology 2012;79(2):145–51.
3. Svalheim S, Røste LS, Nakken KO, Taubøll E. Bone health in adults with epilepsy. Acta Neurol Scand Suppl 2011;(191):89– 95.
4. Miziak B, Chrościńska-Krawczyk M, Czuczwar SJ. An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs. Expert Opin Drug Saf 2019;18(8):679–89.
5. Fahmy EM, Rashed LA, Ismail RS, Helmy H, Mekkawy DA. Evaluation of bone health among epileptic patients using biochemical markers and DEXA scan: an Egyptian study. Egypt J Neurol Psychiatr Neurosurg 2018;54(1):10.
6. Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res 2014;108(8):1352–6.
7. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008;87(4):1080S– 6S.
8. Chaudhuri JR, Mridula KR, Alladi S, Anamika A, Umamahesh M, Balaraju B, et al. Serum 25-hydroxyvitamin d deficiency in ischemic stroke and subtypes in Indian patients. J Stroke 2014;16(1):44–50.
9. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(6 Suppl):1689S–96S.
10. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012;33(3):456–92.
11. Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism-a longitudinal study. Seizure 2010;19(3):153–8.
12. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266– 81.
13. Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 2011;13(4):346–54.
14. Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol 2007;14(4):196–200.
15. Nissen-Meyer LS, Svalheim S, Taubøll E, Gjerstad L, Reinholt FP, Jemtland R. How can antiepileptic drugs affect bone mass, structure and metabolism? Lessons from animal studies. Seizure 2008;17(2):187–91.
16. Lee SH, Yu J. Risk factors of vitamin D deficiency in children with epilepsy taking anticonvulsants at initial and during follow-up. Ann Pediatr Endocrinol Metab 2015;20(4):198–205.
17. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72(3):690–3.
18. Miziak B, Błaszczyk B, Chrościńska-Krawczyk M, Danilkiewicz G, Jagiełło-Wójtowicz E, Czuczwar SJ. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf 2014;13(7):935–46.
19. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011;1814(1):186–99.
20. Sreedharan M, Devadathan K, Mohammed Kunju PA, Sasidharan B, Pillai JP, Vasumathy Amma MA, et al. Vitamin D Deficiency in Ambulant Children on Carbamazepine or Sodium Valproate Monotherapy. Indian Pediatr 2018;55(4):307–10.
21. Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007;10(2):291–5.
22. Suljic EM, Mehicevic A, Mahmutbegovic N. Effect of Longterm Carbamazepine Therapy on Bone Health. Med Arch 2018;72(4):262–66.
23. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43(12):1488– 92.
24. Pack AM, Morrell MJ, McMahon DJ, Shane E. Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs. Epilepsy Behav 2011;21(4):453–8.
25. Fan HC, Lee HS, Chang KP, Lee YY, Lai HC, Hung PL, et al. The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism. Int J Mol Sci 2016;17(8):1242.
26. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47(3):510–5.
27. Cansu A, Yesilkaya E, Serdaroğlu A, Hirfanoğlu TL, Camurdan O, Gülbahar O, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 2008;39(4):266–71.
28. Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010;112(1):1–10.
29. Cetinkaya Y, Kurtulmuş YS, Tutkavul K, Tireli H. The effect of oxcarbazepine on bone metabolism. Acta Neurol Scand 2009;120(3):170–5.
30. Babacan O, Karaoglu A, Vurucu S, Yesilkaya E, Yesilyurt O, Cayci T, et al. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism? J Clin Neurol 2012;8(1):65–8.
31. Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther Adv Musculoskelet Dis 2011;3(5):235–43.
32. Petty SJ, Milligan CJ, Todaro M, Richards KL, Kularathna PK, Pagel CN, et al. The antiepileptic medications carbamazepine and phenytoin inhibit native sodium currents in murine osteoblasts. Epilepsia 2016;57(9):1398–405.
33. Wu FJ, Sheu SY, Lin HC. Osteoporosis is associated with antiepileptic drugs: a population-based study. Epileptic Disord 2014;16(3):333–42.
34. Chaudhuri JR, Mridula KR, Rathnakishore C, Balaraju B, Bandaru VS. Association of 25-Hydroxyvitamin D Deficiency in Pediatric Epileptic Patients. Iran J Child Neurol 2017;11(2):48–56.
35. Albaghdadi O, Alhalabi MS, Alourfi Z, Youssef LA. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. Clin Neurol Neurosurg 2016;146:52–6.
36. Lee HS, Wang SY, Salter DM, Wang CC, Chen SJ, Fan HC. The impact of the use of antiepileptic drugs on the growth of children. BMC Pediatr 2013;13:211.
37. Verrotti A, Agostinelli S, Coppola G, Parisi P, Chiarelli F. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur J Neurol 2010;17(2):232–7.
38. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62(11):2051–7.
39. Rauchenzauner M, Griesmacher A, Tatarczyk T, Haberlandt E, Strasak A, Zimmerhackl LB, et al. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol 2010;52(3):283–8.
40. Durá-Travé T, Gallinas-Victoriano F, Malumbres-Chacón M, Moreno-Gónzalez P, Aguilera-Albesa S, Yoldi-Petri ME. Vitamin D deficiency in children with epilepsy taking valproate and levetiracetam as monotherapy. Epilepsy Res 2018;139:80–4.
41. Xu Z, Jing X, Li G, Sun J, Guo H, Hu Y, et al. Valproate decreases vitamin D levels in pediatric patients with epilepsy. Seizure 2019;71:60–5.
42. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42(9):1141–7.
43. Nissen-Meyer LS, Svalheim S, Taubøll E, Reppe S, Lekva T, Solberg LB, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007;48(10):1850–60.
44. Fekete S, Simko J, Gradosova I, Malakova J, Zivna H, Palicka V, Zivny P. The effect of levetiracetam on rat bone mass, structure and metabolism. Epilepsy Res 2013;107(1-2):56–60. 45. Beniczky SA, Viken J, Jensen LT, Andersen NB. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure 2012;21(6):471–2.
46. Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 2013;104(1-2):134–9.
47. Serin HM, Koç ZP, Temelli B, Esen İ. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine. Epilepsy Behav 2015;51:221–4.
48. Aksoy D, Güveli BT, Ak PD, Sarı H, Ataklı D, Arpacı B. Effects of Oxcarbazepine and Levetiracetam on Calcium, Ionized Calcium, and 25-OH Vitamin-D3 Levels in Patients with Epilepsy. Clin Psychopharmacol Neurosci 2016;14(1):74–8.
49. Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59(5):781– 6.
50. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008;17(2):181–6.
51. Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 2007;37(4):250–4.
52. El-Haggar SM, Mostafa TM, Allah HMS, Akef GH. Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients. Arq Neuropsiquiatr 2018;76(7):452–8.
53. Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan Gel-H. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 2006;67(11):2005– 14.
54. Holló A, Clemens Z, Lakatos P. Epilepsy and vitamin D. Int J Neurosci 2014;124(6):387–93.

APA	Öztürk O, Alpaydın Baslo S, Atakli H, Söylemez E, Aksoy D (2020). Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. , 115 - 122. 10.14744/epilepsi.2019.83788
Chicago	Öztürk Oya,Alpaydın Baslo Sezin,Atakli Hayrunisa Dilek,Söylemez Elif,Aksoy Duygu Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. (2020): 115 - 122. 10.14744/epilepsi.2019.83788
MLA	Öztürk Oya,Alpaydın Baslo Sezin,Atakli Hayrunisa Dilek,Söylemez Elif,Aksoy Duygu Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. , 2020, ss.115 - 122. 10.14744/epilepsi.2019.83788
AMA	Öztürk O,Alpaydın Baslo S,Atakli H,Söylemez E,Aksoy D Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. . 2020; 115 - 122. 10.14744/epilepsi.2019.83788
Vancouver	Öztürk O,Alpaydın Baslo S,Atakli H,Söylemez E,Aksoy D Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. . 2020; 115 - 122. 10.14744/epilepsi.2019.83788
IEEE	Öztürk O,Alpaydın Baslo S,Atakli H,Söylemez E,Aksoy D "Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi." , ss.115 - 122, 2020. 10.14744/epilepsi.2019.83788
ISNAD	Öztürk, Oya vd. "Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi". (2020), 115-122. https://doi.org/10.14744/epilepsi.2019.83788

APA	Öztürk O, Alpaydın Baslo S, Atakli H, Söylemez E, Aksoy D (2020). Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. Epilepsi, 26(2), 115 - 122. 10.14744/epilepsi.2019.83788
Chicago	Öztürk Oya,Alpaydın Baslo Sezin,Atakli Hayrunisa Dilek,Söylemez Elif,Aksoy Duygu Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. Epilepsi 26, no.2 (2020): 115 - 122. 10.14744/epilepsi.2019.83788
MLA	Öztürk Oya,Alpaydın Baslo Sezin,Atakli Hayrunisa Dilek,Söylemez Elif,Aksoy Duygu Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. Epilepsi, vol.26, no.2, 2020, ss.115 - 122. 10.14744/epilepsi.2019.83788
AMA	Öztürk O,Alpaydın Baslo S,Atakli H,Söylemez E,Aksoy D Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. Epilepsi. 2020; 26(2): 115 - 122. 10.14744/epilepsi.2019.83788
Vancouver	Öztürk O,Alpaydın Baslo S,Atakli H,Söylemez E,Aksoy D Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi. Epilepsi. 2020; 26(2): 115 - 122. 10.14744/epilepsi.2019.83788
IEEE	Öztürk O,Alpaydın Baslo S,Atakli H,Söylemez E,Aksoy D "Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi." Epilepsi, 26, ss.115 - 122, 2020. 10.14744/epilepsi.2019.83788
ISNAD	Öztürk, Oya vd. "Epilepsi Hastalarında Antiepileptik İlaçlar ve D Vitamini Eksikliği İlişkisi". Epilepsi 26/2 (2020), 115-122. https://doi.org/10.14744/epilepsi.2019.83788